In deliberations yesterday the Centers for Disease Control and Prevention (CDC) vaccine advisory group recommended updated COVID-19 and flu vaccines for the upcoming respiratory virus season, with people ages 6 months and older advised to receive the vaccine in most circumstances.

The Advisory Committee for Immunization Practices (ACIP) made one tweak to the flu vaccine recommendation, which is that solid-organ transplant recipients who are ages 18 to 64 years old may receive an adjuvanted or high-dose flu vaccine as an off-label option.
In a CDC statement accepting the group's recommendation, CDC Director Mandy Cohen, MD, MPH, said the top recommendation for protecting people and their loved ones from respiratory illness is to get vaccinated. "Make a plan now for you and your family to get both updated flu and COVID vaccines this fall, ahead of the respiratory virus season."
21-strain pneumococcal vaccine recommended
ACIP also unanimously voted to recommend Merck's new 21-valent (21-strain) pneumococcal vaccine as an option for adults ages 65 and older who have not received one or whose vaccination status isn't known. The advisers also said the vaccine could be used in the age-group with shared clinical decision-making on a supplemental basis in those who have completed their vaccine series with pneumococcal conjugate vaccine 13 (PCV13, which includes 13 strains) or pneumococcal polysaccharide vaccine 23 (PPSV23, the 23-strain version).
Make a plan now for you and your family to get both updated flu and COVID vaccines this fall.
The group also recommended a single dose of the vaccine in patients ages 19 to 64 who have certain underlying health conditions, both those who haven't received a dose of pneumococcal conjugate vaccine and those who started their series with PCV13 but have not received all recommended PPSV23 doses.